Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Bryostatin-1 by Synaptogenix for Multiple Sclerosis: Likelihood of Approval
Bryostatin-1 is under clinical development by Synaptogenix and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase I...